Dr. Mark Kiel is the chief scientific officer at Genomenon, where he oversees the company's scientific direction and product development. Mark received his MD/PhD in Clinical Pathology at the University of Michigan, and founded Genomenon to address the challenge of connecting pharma researchers with evidence in the literature to help diagnose and treat patients with rare genetic diseases and cance